Undisclosed (Targeting alpha-synuclein)
Neurodegeneration (e.g., Parkinson's Disease)
Pre-clinicalActive
Key Facts
Indication
Neurodegeneration (e.g., Parkinson's Disease)
Phase
Pre-clinical
Status
Active
Company
About Pangolin Therapeutics
Pangolin Therapeutics is an early-stage biotech pioneering a novel approach to drug discovery by targeting intrinsically disordered proteins (IDPs), a large class of proteins previously considered undruggable due to their lack of stable structure. The company's proprietary Pangomer platform aims to generate first-in-class therapeutics with disease-modifying potential, initially focusing on Type 2 Diabetes and neurodegeneration. Led by an experienced team and supported by $9.5M in non-dilutive funding, Pangolin is positioned to build a pipeline in high-need therapeutic areas, presenting opportunities for investment and partnership.
View full company profile